NCR Online Journal

Chronic Kidney Disease Pipeline Landscape Analysis: 50+ Key Players & 50+ Pipeline Drugs

 Breaking News
  • No posts were found

Chronic Kidney Disease Pipeline Landscape Analysis: 50+ Key Players & 50+ Pipeline Drugs

November 17
19:57 2022
Chronic Kidney Disease Pipeline Landscape Analysis: 50+ Key Players & 50+ Pipeline Drugs

DelveInsight’s, “Chronic Kidney Disease Pipeline Insights, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Chronic Kidney Disease Pipeline Insights Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Chronic Kidney Disease Pipeline Insights Report

  • DelveInsight’s Chronic Kidney Disease Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
  • The Chronic Kidney Disease Companies are working such as KBP Biosciences, Eli Lilly and Company, Novo Nordisk, Prokidney, Boryung Pharmaceutical, Boehringer Ingelheim, Cadila Healthcare Limited, AM-Pharma, DiaMedica Therapeutics, Allena Pharmaceuticals, AstraZeneca, Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Scohia Pharma, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Oisin, Biotechnologies, Aria Pharmaceuticals, RedHill Biopharma, BERGENBIO, GNI Group, and others are evaluating novel hypertension drugs candidate to improve the treatment landscape.
  • Promising Chronic Kidney Disease Pipeline Therapies such as roxadustat, Monofer, AZD5718, MEDI8367, rHuEPO, AST-120, KBP-5074, Empagliflozin, ALLN-346, US-APR2020, MEDI8367, and others.
  • The Chronic Kidney Disease Companies and academics are working to assess challenges and seek opportunities that could influence Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Kidney Disease.

 

Recent Developmental Activities in the Chronic Kidney Disease Pipeline Report

  • Medi8367 is an antibody which is used to treat Chronic Kidney Disease. It specifically binds human integrin β8 and works allosterically reducing its affinity for the LAP domain, hence preventing β8-mediated TGFβ activation but not its cell adhesion function.
  • US-APR2020 is a natural probiotics formulation that metabolizes nitrogenous waste, which generally diffuses from the circulating bloodstream into the bowel. When these waste products accumulate in high concentrations in the blood, they become highly toxic and can cause severe damage to many organ systems if they are not properly excreted. US-APR2020 utilizes nitrogenous wastes as nutrients. As probiotics grow and multiply, they consume more nitrogenous waste and effectively maintain healthy kidney function.
  • ALLN-346 is an investigational first-in-class, non-absorbed, orally administered enzyme for the treatment of hyperuricemia and gout, a metabolic disorder characterized by high systemic levels of urate that can lead to several complications, including arthritis, kidney stones, and CKD.
  • Empagliflozin (BI10773) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for chronic kidney disease.
  • KBP Biosciences’ lead product candidate, KBP-5074, is a potentially best-in-class, next-generation, non-steroidal MRA discovered and developed by KBP’s scientists, is being developed globally to initially treat Stage 3b/4, or moderate-to-severe, CKD patients with uncontrolled hypertension. KBP-5074 selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors, suggesting that KBP-5074 should be effective in blocking the hypertensive and renal tissue damaging effects of aldosterone with reduced risk of pro-diabetic and adverse endocrine effects. In clinical trials conducted to-date, it has demonstrated an ability to lower blood pressure without androgenic effects such as hirsutism, obesity and gynecomastia. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Uncontrolled Hypertension and Moderate or Severe CKD.

 

Request a sample and discover the recent advances in Chronic Kidney Disease Medication @ Chronic Kidney Disease Clinical Trials Analysis

 

Chronic Kidney Disease Overview

Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease. People with chronic kidney disease may not feel ill or notice any symptoms. CKD signs and symptoms develop over time if kidney damage progresses slowly. Loss of kidney function can cause a buildup of fluid or body waste or electrolyte problems. The most common symptoms of chronic kidney disease include: hypertension, anemia, edema, fatigue, decreased urine output, blood in urine, dark urine, loss of appetite and persistent itchy skin. Patients feel unwell or have symptoms with mild-to-moderate chronic kidney disease that is, stages 1 to 3.

Chronic kidney disease is usually diagnosed by the eGFR test before any symptoms develop. Symptoms tend to develop when chronic kidney disease becomes severe (stage 4) or worse. The symptoms at first tend to be vague and nonspecific, such as feeling tired, having less energy than usual and just not feeling well. The most common cause of chronic kidney disease is diabetes and high blood pressure. Each kidney contains about 1 million tiny filtering units, called nephrons. Any disease that injures or scars the nephrons can cause kidney disease. Diabetes and high blood pressure can both damage the nephrons. High blood pressure can also damage the blood vessels of your kidneys, heart, and brain. The kidneys are highly vascularized, meaning they contain lots of blood vessels. So, blood vessel diseases are generally dangerous to your kidneys. If uncontrolled, or poorly controlled, high blood pressure can be a leading cause of heart attacks, strokes and chronic kidney disease. Also, chronic kidney disease can cause high blood pressure. Chronic kidney disease (CKD) has no cure, but treatment can help relieve symptoms and prevent it from worsening. While the damage to your kidneys cannot be reversed, precautions to maintain them as healthy for as long as possible. The treatment will depend on the stage of CKD.

 

Chronic Kidney Disease Emerging Drugs

  • KBP-5074: KBP Biosciences
  • Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company
  • ALLN-346: Allena Pharmaceuticals
  • US-APR2020: Kibow Pharma
  • MEDI8367: AstraZeneca

 

Chronic Kidney Disease Pipeline Therapeutic Analysis

There are approx. 50+ key companies which are developing the therapies for Chronic Kidney Disease. The companies which have their Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase III include, KBP Biosciences.

 

Learn more about the emerging Chronic Kidney Disease pipeline therapies @ Chronic Kidney Disease Treatment Landscape Analysis

 

Scope of the Chronic Kidney Disease Pipeline Report

  • Coverage- Global
  • Chronic Kidney Disease Pipeline Assessment by Product Type
  • Chronic Kidney Disease Pipeline Assessment by Stage and Product Type
  • Chronic Kidney Disease Pipeline Assessment by Route of Administration
  • Chronic Kidney Disease Pipeline Assessment by Stage and Route of Administration
  • Chronic Kidney Disease Pipeline Assessment by Molecule Type
  • Chronic Kidney Disease Pipeline Assessment by Stage and Molecule Type
  • Chronic Kidney Disease Companies- KBP Biosciences, Eli Lilly and Company, Novo Nordisk, Prokidney, Boryung Pharmaceutical, Boehringer Ingelheim, Cadila Healthcare Limited, AM-Pharma, DiaMedica Therapeutics, Allena Pharmaceuticals, AstraZeneca, Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Scohia Pharma, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Oisin, Biotechnologies, Aria Pharmaceuticals, RedHill Biopharma, BERGENBIO, GNI Group, and others
  • Chronic Kidney Disease Pipeline Therapies- roxadustat, Monofer, AZD5718, MEDI8367, rHuEPO, AST-120, KBP-5074, Empagliflozin, ALLN-346, US-APR2020, MEDI8367, and others

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Kidney Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Kidney Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug Name : Company Name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. KBP-5074: KBP Biosciences
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. ALLN-346: Allena Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. MEDI8367: AstraZeneca
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Chronic Kidney Disease Key Companies
  21. Chronic Kidney Disease Key Products
  22. Chronic Kidney Disease – Unmet Needs
  23. Chronic Kidney Disease – Market Drivers and Barriers
  24. Chronic Kidney Disease – Future Perspectives and Conclusion
  25. Chronic Kidney Disease Analyst Views
  26. Chronic Kidney Disease Key Companies
  27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Chronic Kidney Disease drugs?
  • How many Chronic Kidney Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Kidney Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Got Queries? Get in touch with our Business Development Executive @ Chronic Kidney Disease Drugs

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles